Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era

DOI record: { "DOI": "10.1371/journal.pone.0279326", "ISSN": [ "1932-6203" ], "URL": "http://dx.doi.org/10.1371/journal.pone.0279326", "abstract": "<jats:p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are expected to be resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real-world experience regarding its effectiveness is scarce. This retrospective cohort study reports a data analysis in Banner Healthcare System (a large not-for-profit organization) between 4/5/2022 and 8/1/2022 and included 19,778 Coronavirus disease-19 (COVID-19) positive (by PCR or direct antigen testing) patients who were selected from Cerner-Electronic Health Record after the exclusions criteria were met. The study index date for cohort was determined as the date of BEB MAb administration or the date of the first positive COVID-19 testing. The cohort consist of COVID-19 infected patients who received BEB MAb (N = 1,091) compared to propensity score (PS) matched control (N = 1,091). The primary composite outcome was the incidence of 30-day all-cause hospitalization and/or mortality. All statistical analyses were conducted on the paired (matched) dataset. For the primary composite outcome, the event counts and percentages were reported. Ninety-five percent Clopper-Pearson confidence intervals for percentages were computed. The study cohorts were 1:1 propensity matched without replacement across 26 covariates using an optimal matching algorithm that minimizes the sum of absolute pairwise distance across the matched sample after fitting and using logistic regression as the distance function. The pairs were matched exactly on patient vaccination status, BMI group, age group and diabetes status. Compared to the PS matched control group (2.6%; 95% confidence interval [CI]: 1.7%, 3.7%), BEB MAb use (2.2%; 95% CI: 1.4%, 3.3%) did not significantly reduce the incidence of the primary outcome (p = 0.67). In the subgroup analysis, we observed similar no-difference trends regarding the primary outcomes for the propensity rematched BEB MAb treated and untreated groups, stratified by patient vaccination status, age (&lt;65 years or ≥65), and immunocompromised status (patients with HIV/AIDS or solid organ transplants or malignancy including lymphoproliferative disorder). The number needed to treat (1/0.026–0.022) with BEB MAb was 250 to avoid one hospitalization and/or death over 30 days. The BEB MAb use lacked efficacy in patients with SARS-CoV-2 Omicron subvariants (mainly BA.2, BA.2.12.1, and BA.5) in the Banner Healthcare System in the Southwestern United States.</jats:p>", "author": [ { "affiliation": [], "family": "Sridhara", "given": "Srilekha", "sequence": "first" }, { "affiliation": [], "family": "Gungor", "given": "Ahmet B.", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-5760-4276", "affiliation": [], "authenticated-orcid": true, "family": "Erol", "given": "Halil K.", "sequence": "additional" }, { "affiliation": [], "family": "Al-Obaidi", "given": "Mohanad", "sequence": "additional" }, { "affiliation": [], "family": "Zangeneh", "given": "Tirdad T.", "sequence": "additional" }, { "affiliation": [], "family": "Bedrick", "given": "Edward J.", "sequence": "additional" }, { "affiliation": [], "family": "Ariyamuthu", "given": "Venkatesh K.", "sequence": "additional" }, { "affiliation": [], "family": "Shetty", "given": "Aneesha", "sequence": "additional" }, { "affiliation": [], "family": "Qannus", "given": "Abd A.", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-9618-2336", "affiliation": [], "authenticated-orcid": true, "family": "Mendoza", "given": "Katherine", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-9145-5283", "affiliation": [], "authenticated-orcid": true, "family": "Murugapandian", "given": "Sangeetha", "sequence": "additional" }, { "affiliation": [], "family": "Gupta", "given": "Gaurav", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-2378-9302", "affiliation": [], "authenticated-orcid": true, "family": "Tanriover", "given": "Bekir", "sequence": "additional" } ], "container-title": "PLOS ONE", "container-title-short": "PLoS ONE", "content-domain": { "crossmark-restriction": false, "domain": [ "www.plosone.org" ] }, "created": { "date-parts": [ [ 2023, 4, 28 ] ], "date-time": "2023-04-28T17:25:19Z", "timestamp": 1682702719000 }, "deposited": { "date-parts": [ [ 2023, 4, 28 ] ], "date-time": "2023-04-28T17:25:51Z", "timestamp": 1682702751000 }, "editor": [ { "affiliation": [], "family": "Molla", "given": "Md Maruf Ahmed", "sequence": "first" } ], "funder": [ { "name": "Shionogi Inc. and La Jolla pharmaceuticals" }, { "DOI": "10.13039/501100019123", "doi-asserted-by": "publisher", "name": "AiCuris" } ], "indexed": { "date-parts": [ [ 2023, 4, 29 ] ], "date-time": "2023-04-29T04:34:58Z", "timestamp": 1682742898480 }, "is-referenced-by-count": 0, "issue": "4", "issued": { "date-parts": [ [ 2023, 4, 28 ] ] }, "journal-issue": { "issue": "4", "published-online": { "date-parts": [ [ 2023, 4, 28 ] ] } }, "language": "en", "license": [ { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 4, 28 ] ], "date-time": "2023-04-28T00:00:00Z", "timestamp": 1682640000000 } } ], "link": [ { "URL": "https://dx.plos.org/10.1371/journal.pone.0279326", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "340", "original-title": [], "page": "e0279326", "prefix": "10.1371", "published": { "date-parts": [ [ 2023, 4, 28 ] ] }, "published-online": { "date-parts": [ [ 2023, 4, 28 ] ] }, "publisher": "Public Library of Science (PLoS)", "reference": [ { "DOI": "10.1001/jama.2020.2648", "article-title": "Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention.", "author": "Z Wu", "doi-asserted-by": "crossref", "first-page": "1239", "issue": "13", "journal-title": "JAMA", "key": "pone.0279326.ref001", "volume": "323", "year": "2020" }, { "key": "pone.0279326.ref002", "unstructured": "CDC COVID19 Symptoms. Available on https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Accessed on 2/25/2023." }, { "DOI": "10.15585/mmwr.mm6924e2", "article-title": "Coronavirus Disease 2019 Case Surveillance—United States, January 22-May 30, 2020.", "author": "EK Stokes", "doi-asserted-by": "crossref", "first-page": "759", "issue": "24", "journal-title": "MMWR Morb Mortal Wkly Rep.", "key": "pone.0279326.ref003", "volume": "69", "year": "2020" }, { "DOI": "10.1016/S0140-6736(22)00327-0", "article-title": "Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study", "author": "C Menni", "doi-asserted-by": "crossref", "first-page": "1618", "issue": "10335", "journal-title": "Lancet", "key": "pone.0279326.ref004", "volume": "399", "year": "2022" }, { "DOI": "10.1093/infdis/jiac411", "article-title": "Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants", "author": "FP Esper", "doi-asserted-by": "crossref", "first-page": "344", "issue": "3", "journal-title": "J Infect Dis", "key": "pone.0279326.ref005", "volume": "227", "year": "2023" }, { "DOI": "10.1038/s41586-022-04594-4", "article-title": "Antibody evasion properties of SARS-CoV-2 Omicron sublineages", "author": "S Iketani", "doi-asserted-by": "crossref", "first-page": "553", "issue": "7906", "journal-title": "Nature", "key": "pone.0279326.ref006", "volume": "604", "year": "2022" }, { "DOI": "10.1056/NEJMc2207519", "article-title": "Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants", "author": "E Takashita", "doi-asserted-by": "crossref", "first-page": "468", "issue": "5", "journal-title": "N Engl J Med", "key": "pone.0279326.ref007", "volume": "387", "year": "2022" }, { "DOI": "10.1038/s41591-022-01792-5", "article-title": "Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies", "author": "T Bruel", "doi-asserted-by": "crossref", "first-page": "1297", "issue": "6", "journal-title": "Nat Med", "key": "pone.0279326.ref008", "volume": "28", "year": "2022" }, { "key": "pone.0279326.ref009", "unstructured": "US Food and Drug Administration. COVID-19 update: FDA authorizes new monoclonal antibody for treatment of COVID-19 that retains activity against Omicron variant. Available at: https://www.fda.gov/news-events/ press-announcements/coronavirus-covid-19-update-fdaauthorizes-new-monoclonal-antibody-treatment-covid-19-retains. Accessed on November 11, 2022." }, { "DOI": "10.1371/journal.pone.0278770", "article-title": "The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants.", "author": "HB Gershengorn", "doi-asserted-by": "crossref", "first-page": "e0278770", "issue": "12", "journal-title": "PLoS One", "key": "pone.0279326.ref010", "volume": "17", "year": "2022" }, { "DOI": "10.1101/2022.03.10.22272100", "doi-asserted-by": "crossref", "key": "pone.0279326.ref011", "unstructured": "Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. medRxiv. Preprint and has not been peer-reviewed. Available at https://doi.org/10.1101/2022.03.10.22272100." }, { "key": "pone.0279326.ref012", "unstructured": "CDC COVID19 Underlying Medical Conditions. Available on https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed on 2/25/2023." }, { "DOI": "10.1093/ofid/ofac517", "article-title": "Evaluation of Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era.", "author": "EK McCreary", "doi-asserted-by": "crossref", "first-page": "ofac517", "issue": "10", "journal-title": "Open Forum Infect Dis.", "key": "pone.0279326.ref013", "volume": "9", "year": "2022" }, { "DOI": "10.1093/infdis/jiac346", "article-title": "Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch", "author": "O Razonable RR", "doi-asserted-by": "crossref", "first-page": "1683", "issue": "10", "journal-title": "J Infect Dis", "key": "pone.0279326.ref014", "volume": "226", "year": "2022" }, { "key": "pone.0279326.ref015", "unstructured": "CoVariants. Available at https://covariants.org/, accessed on 11/10/2022." }, { "DOI": "10.1080/00273171.2011.568786", "article-title": "An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies.", "author": "PC Austin", "doi-asserted-by": "crossref", "first-page": "399", "issue": "3", "journal-title": "Multivariate Behav Res.", "key": "pone.0279326.ref016", "volume": "46", "year": "2011" }, { "DOI": "10.1198/106186006X137047", "article-title": "Optimal Full Matching and Related Designs via Network Flows", "author": "Ben B Hansen", "doi-asserted-by": "crossref", "first-page": "609", "issue": "3", "journal-title": "Journal of Computational and Graphical Statistics", "key": "pone.0279326.ref017", "volume": "15", "year": "2006" }, { "key": "pone.0279326.ref018", "unstructured": "Arizona State Immunization Information System [ASIIS], available at https://asiis.azdhs.gov/, accessed on 11/12/2022." }, { "DOI": "10.15585/mmwr.mm7137a4", "article-title": "Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods—United States, April 2020-June 2022.", "author": "S Adjei", "doi-asserted-by": "crossref", "first-page": "1182", "issue": "37", "journal-title": "MMWR Morb Mortal Wkly Rep", "key": "pone.0279326.ref019", "volume": "71", "year": "2022" }, { "DOI": "10.1038/s41586-022-04980-y", "article-title": "BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection", "author": "Y Cao", "doi-asserted-by": "crossref", "first-page": "593", "issue": "7923", "journal-title": "Nature", "key": "pone.0279326.ref020", "volume": "608", "year": "2022" }, { "DOI": "10.1016/j.celrep.2022.110812", "article-title": "LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.", "author": "K Westendorf", "doi-asserted-by": "crossref", "first-page": "110812", "issue": "7", "journal-title": "Cell Rep", "key": "pone.0279326.ref021", "volume": "39", "year": "2022" }, { "DOI": "10.1097/TP.0000000000004278", "article-title": "Bebtelovimab for Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients", "author": "T Shertel", "doi-asserted-by": "crossref", "first-page": "e463", "issue": "10", "journal-title": "Transplantation", "key": "pone.0279326.ref022", "volume": "106", "year": "2022" }, { "DOI": "10.1111/tid.13901", "article-title": "Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.", "author": "ZA Yetmar", "doi-asserted-by": "crossref", "first-page": "e13901", "issue": "4", "journal-title": "Transpl Infect Dis", "key": "pone.0279326.ref023", "volume": "24", "year": "2022" }, { "key": "pone.0279326.ref024", "unstructured": "The NIH COVID-19 Treatment Guidelines Panel’s Statement on Omicron Subvariants, Pre-Exposure Prophylaxis, and Therapeutic Management of Nonhospitalized Patients With COVID-19. Available at: https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-omicron-subvariants/. Accessed on November 20, 2022." }, { "article-title": "Fact sheet for healthcare providers: Emergency Use Authorization for bebtelovimab.", "author": "Food and Drug Administration", "key": "pone.0279326.ref025", "year": "2022" }, { "article-title": "Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution.", "author": "Y Cao", "journal-title": "bioRxiv", "key": "pone.0279326.ref026", "year": "2022" }, { "key": "pone.0279326.ref027", "unstructured": "FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region. Avaiable at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region. Accessed on December 3, 2022." }, { "DOI": "10.1038/s41576-022-00478-5", "article-title": "The human genetic epidemiology of COVID-19", "author": "MEK Niemi", "doi-asserted-by": "crossref", "first-page": "533", "issue": "9", "journal-title": "Nat Rev Genet", "key": "pone.0279326.ref028", "volume": "23", "year": "2022" }, { "DOI": "10.1038/s41586-020-2818-3", "article-title": "The major genetic risk factor for severe COVID-19 is inherited from Neanderthals", "author": "H Zeberg", "doi-asserted-by": "crossref", "first-page": "610", "issue": "7835", "journal-title": "Nature", "key": "pone.0279326.ref029", "volume": "587", "year": "2020" }, { "DOI": "10.1016/j.gene.2022.146674", "article-title": "The association of COVID-19 severity and susceptibility and genetic risk factors: A systematic review of the literature", "author": "A Ishak", "doi-asserted-by": "crossref", "first-page": "146674", "journal-title": "Gene", "key": "pone.0279326.ref030", "volume": "836", "year": "2022" }, { "DOI": "10.1038/s41586-022-04576-6", "article-title": "Whole-genome sequencing reveals host factors underlying critical COVID-19", "author": "A Kousathanas", "doi-asserted-by": "crossref", "first-page": "97", "issue": "7917", "journal-title": "Nature", "key": "pone.0279326.ref031", "volume": "607", "year": "2022" } ], "reference-count": 31, "references-count": 31, "relation": {}, "resource": { "primary": { "URL": "https://dx.plos.org/10.1371/journal.pone.0279326" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Multidisciplinary" ], "subtitle": [], "title": "Lack of effectiveness of Bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1371/journal.pone.corrections_policy", "volume": "18" }